Introduction Erlotinib is a well known FDA approved drug from category of tyrosine kinase
inhibitors; used for the treatment of lung cancer. However its use is limited because of its …

Erlotinib hydrochloride, a selective tyrosine kinase inhibitor approved for treatment of non-
small cell lung cancer firstly. Erlotinib classified as class II drugs in the Biopharmaceutical …

Poor water solubility and low oral bioavailability limit the clinical application of Erlotinib as
an anticancer. For this purpose, we encapsulated erlotinib in the solid lipid nanoparticles …

Erlotinib is a tyrosine kinase inhibitor and it can treat tumors, such as pancreatic and locally
advanced lung cancer or metastatic cancer. The traditional formulation of erlotinib currently …

Abstract Background and objectives Erlotinib HCl is approved for the treatment of metastatic
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …

Non-small cell lung cancer (NSCLC) is a global concern as one of the leading causes of
cancer deaths. The treatment options for NSCLC are limited to systemic chemotherapy …

This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

The present investigation demonstrates the preparation of solid self nanoemulsfying drug
delivery system (sSNEDDS) to enhance stability and bioavailability of Erlotinib (ERL) via the …

The most common cause of deaths due to cancers nowadays is lung cancer. The objective
of this study was to prepare erlotinib loaded chitosan nanoparticles for their anticancer …

To improve the solubility and oral bioavailability of erlotinib, a poorly water-soluble
anticancer drug, solid self-emulsifying drug delivery system (SEDDS) was developed using …